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control in this population. Specifically, it is unknown whether the normal nocturnal decline 
in BP is present in patients with LVAD. 
METHODS: Twenty-four hour ambulatory BP and LVAD rate were measured in 10 
patients (six males/four females, mean age 54 ± 13 years) who had received a LVAD for 
cardiogenic shock. Etiology of cardiac dysfunction was ischemic in four patients, non- 
ischemic in five patients, and hypertrophic in one patient. Patients were clinically stable 
out of the intensive care unit and were not on inotropic support. Nine of the patients were 
on anti-hypertensive therapy. 
RESULTS; When comparing daytime and nighttime mean readings, there was no signifi- 
cant change in systolic, diastolic, or mean BP or in LVAD rate. 
CONCLUSION: Similar to patients with congestive heart failure or cardiac transplanta- 
tion, patients with LVAD lack a normal nocturnal decline in BP. This abnormal paffem of 
BP increases the cumulative work of the device by continuous 24 hour exposure to high 
afterload. Therefore, more aggressive treatment of hypertension in patients with left ven- 
tricular assist devices may be warranted to reduce the lanai-term workload of the device. 
Vital Sign Day (8AM-8PM) Night (12AM-6AM) p Value 
Systolic Blood Pressure (mm Hg) 125 + t0 120 ± 12 NS 
Diastolic Blood Pressure (mm Hg) 72 ± 11 69 ± 10 NS 
Mean Arterial Pressure (rnm Hg) 90 ± 8 87 ± 9 NS 
LVAD Rate (beats/min) 75 + 19 75 + 20 NS 
by fortnightly intramuscular injection. Exercise tolerance was assessed by the incremen- 
tal shuttle walk test; symptoms by NYHA class, Minnesota Living with Heart Failure 
(MLHF) score and Beck Depression Inventory (BDI); cardiac function by echocardio- 
graphy. Skeletal muscle bulk was estimated by CT-computed cross-sectional area of 
mid-thigh and mid-calf muscle; hand-grip strength was measured by dynamometry. Data 
are as mean±SD and were analysed by Wilcoxon matched pairs and Mann-Whitney U 
test. 
Result=l: Baseline characteristics did not differ significantly between groups. Mean test- 
osterone level at baseline was 12.71-6.4nM (normal range 10-37nM). Exercise distance 
increased markedly in the active treatment group (from 328+174m to 419±200m, p=0.01) 
but not in the placebo group (from 314±92m to 340~101m, p=0.12). The increase in walk 
distance in the two groups differed significantly (28% v 8% increase, p=0.015). NYHA 
class improved with treatment (from 2.3_+0.5 to 1.9±0.7. p=0.046), as did MLHF score 
(34.5±29.2 to 26.5:~:25.2, p=0.05) and BDI score (7.3±7.3 to 5.7~6.0, p=0.03). There 
were no changes in left ventricular function or in measures of skeletal muscle bulk and 
grip strength. 
Conclusion: In a pilot study, testosterone therapy for men with chronic heart failure 
improved exercise duration, symptom scores and mood with no apparent effect on LV 
function or skeletal muscle and no reported adverse effects. This may prove a useful 
add-on therapy for improving functional capacity and symptoms in these patients. 
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808-5 Ident i f i cat ion of  Left  Ventricular Recovery on 
Mechanical Assist Devices: Acute Suppor t  for  
Postcardiotomy Shock Versus Chronic Support as a 
Bridge to Transplant 
John Gorcsan. III. Donald A. Severyn, Badley P. Gdffith, Robert L. Karmas, University of 
Pittsburg, Pittsburg, Pennsylvania. 
Left ventricular assist devices (LVAD) can be life saving for acute heart failure (HF) asso- 
ciated with post-cardiotomy shock and also severe HF as a bridge to transplant. To test 
the hypothesis that quantitative echo measures can detect LV recovery on LVAD support, 
23 pts were studied: 11 with LVAD for acute post-cardiotomy shock (support duration 5±1 
d) and 12 with LVAD as bridge to transplant (support 276±191 d). Acute devices were 6 
Abiomed, 5 Biomedicus. Chronic devices were 6 Novacor, 6 Thoratec. LV end-diastolic 
and end-systolic area measures were made during full VAD support (acute flow=4.5±0.5, 
chronic flow=6.1+l.3L/min) and during decreases in VAD flow (acute 
flow=l.6+0.6,chronic flow=3.0±O.6L/min). 8 patients with acute support and 4 with 
chronic support had successful LVAD removal and survived to hospital discharge. Signif- 
icant differences were observed between the LV recovery patients on acute vs. chronic 
support as follows: % 8 in LV fractional area change (acute=77+55% vs chronic=- 
3+10%,p<0.05) and %8 in stroke area (acute=105±54% vs chronic=l 9±18%,p<0.05) fol- 
lowing weaning to low flow. Conclusions Quantitative echo detected LV recovery and 
predicted successful device removal in patients on both acute and chronic LVAD support. 
Recovery from acute shock was associated with greater degrees of LV functional 
improvement han patients on chronic support. Separate criteria need to be used to gov- 
ern the removal of devices with respect to duration of mechanical circulatory support. 
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810-2 Effect of Carvedllol on Major Clinical Events in Patients 
With Severe Heart Failure and an Extremely Depressed 
Ejection Fraction: Results of the COPERNICUS Study 
Hugo A. Katus, Michal Tendera, Paul Mohacsi, Jean L. Rouleau, Michael B. Fowler, 
Andrew J. Coats, Henry Krum, Terry L. Holcslaw, Ellen B. Roecker, Milton Packer, for the 
COPERNICUS Study Group., Universitaets-Klinikum Luebeck, Luebeck, Germany. 
Background: Despite the demonstrated survival benefit of ~-blockers in heart failure 
(HF), many physicians avoid the use of these drugs in patients with extremely depressed 
LV function in the belief that they will not respond favorably or may be adversely affected 
by treatment. 
Methods: Of the 2289 patients with severe HF enrolled in the COPERNICUS trial, 371 
patients had a baseline LV ejection fraction <= 15%. These patients had a lower mean 
systolic blood pressure (117 vs 125 mm Hg) and were more likely to be treated with digi- 
talis (73% vs 65%) than patients with higher EF (both P<0.002) but were otherwise simi- 
lar in their baseline characteristics. Both subgroups of patients were randomized to 
placebo (PBO) or carvedilol (CRY) for up to 29 months. 
Results: Shown below are 1-year Kaplan-Meier rates and risk reductions with CRV (Cox 
model). 
Ejection fraction <= 15% Ejection fraction • 15% 
PBO CRV Reduction PBO CRV Reduction in 
(n=191) (n=180) in risk (n=942) (n=976) risk 
All-cause 23.8% 18.9% 30% 17.4% 9.7% 36% 
mortality 
Death or hospitalization 46.3% 30.3% 39% 36.0% 24.6% 28% 
for worsening HF 
Death or cardiovascular 52.1% 34.6% 41% 39.4% 29.4% 23% 
hospitalization 
Death or any 59.9% 47.2% 33% 50.7% 40.4% 21% 
hospitalization 
The effects of CRV on all-cause mortality and on the risks of death or hospitalization (for 
any reason or for a specific cause) in patients with EF <= 15% were similar to those seen 
in patients with higher EF. CRV reduced the risk of permanent discontinuation of study 
drug in patients with EF <= 15% (by 32%) and in those with higher EF (by 19%). 
Conclusion: CRV is effective and well tolerated even in patients with severe HF symp- 
toms and an extreme depression of LV systolic function. 
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810-1 Testosterone Therapy Improves Exercise Duration and 
Symptoms in Men With Chronic Congestive Heart 
Failure 
Peter J. Push. John N. West, T. Hugh Jones, Kevin S. Channer, Department of 
Cardiology, Royal Ha/lamshire Hospital Sheffield, United Kingdom, Institute of 
Endocrinology, University of Sheffield Medical School Sheffield, United Kingdom. 
Background: Chronic heart failure (CHF) remains a major cause of morbidity, with terri- 
ble prognosis. Relative androgen deficiency reported in men with CHF could contribute 
to the pathophysiological processes of myocardial dysfunction, neuro-hormonal activa- 
tion, catabolic excess and muscle wasting and therefore to symptoms of exercise intoler- 
ance and dyspnoea. We examined the effects of androgen therapy on exercise duration, 
symptoms, cardiac function and skeletal muscle strength and bulk in men with CHF. 
Methods: In a double-blind trial, 20 men with CHF (age 61.5+8.5 years, ejection fraction 
34.8±7.8%) were randomised to 3 months treatment with testosterone 100mg or placebo 
11:30 a.m. 
810-3 Nutritional Supplementation With MyoVive~D Repletes 
Essential Cardiac Myocyte Nutrients and Reduces Left 
Ventricular Size in Patients With Left Ventriculsr 
Dysfunction 
Farida Jeeieebhoy, Mary Keith, Michael Freeman, Aiala Barr, Michele McCall, Regina 
Kudan, David Mazer, Lea Errett, SL Michael's Hospital, Toronto, Ontado, Canada, 
University of Toronto, Toronto, Ontado, Canada. 
Background: Congestive heart failure (CHF) depletes the myocardium of camitine, coen- 
zyme Q10 (CoQ10) and taudne, substances known to influence mitochondrial function 
and cell calcium. We hypothesized that feeding patients a nutritional supplement which 
contains carnitine, CoQ10 and taurine would result in higher myocardial levels and 
improve left ventricular function. 
Methods: Forty-one aortocoronary artery bypass patients with an ejection fraction (EF)< 
40% at referral, were randomized to a double-blind trial of supplement (S) or placebo (P). 
Radionuclide ventriculography was performed at randomization (R) and just prior to sur- 
gery. Surgical myocardial biopsies, adjusted for protein content, were analyzed for car- 
nitine, CoQ10 and taurine levels. 
Results: The groups were well matched. Minor exceptions were S vs P for digoxin use (7 
versus 0 respectively p=0.0087) and age (62±11 versus 69±5 respectively, p=0.0395). 
There were significantly higher levels in the treated as compared to the placebo group for 
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myocardial levels of CoQ10 (138.17±39.87 and 56.67±23.08 nmols/g wet weight 
[p--O,O006]), taudne (13.12+4.00 and 7.91±2.81 umoVg wet weight [p--O.0016]), and car- 
nitine (1735.4+798.5 and 1237.6+343.1 nmoVg wet weight [p=0.056 and p=0.028 one 
tailed]). The left ventdcular end diastolic volume (LVEDV) fell by -7.5+21.7 in the supple- 
mented group and increased by 10.0+19.8 in the placebo fed patients (p=0.037). 
Conclusions: Supplementation results in higher myocardial CoQ10, taudne and camitine 
levels and is associated with a reduction in LVEDV in patients with left ventricular dys- 
function prior to revasculadzation. Since the risk of mortality for surgical revasculadzation 
is related to preoperative LVEDV, supplementation could improve outcomes. 
11:45 a.m. 
810-4 Vasopresein Receptor Blockade in Patients With 
Congestive Heart Failure: Results From a Placebo 
Controlled, Randomized Study Comparing the Effects 
of Tolvaptan, Furosemide, and Their Combination 
Jame~ E. UdelsoD, Cesare Orlandi, Torrance O'Brien, Rafael Sequeira, John Ouyang, 
Marvin A. Konstam, Tufts-New England Medical Center, Boston, Massachusetts. 
Background: Increased vasopressin levels contribute to the progression of heart failure 
(HF) to an unknown degree. The presence of diuretics has confounded prior evaluations 
of vasoprassin receptor antagonists (VRA). We investigated the effects of VRA in the 
absence of a diuretic for the first time, with Tolvaptan (OPC-41061, TLV), a novel, non- 
peptide VRA. 
Methods: Pts with HF (NYHA class I1-111, n=83) and signs of congestion (e.g., edema or 
rales) were removed from baseline diuretic therapy and placed on a low-sodium diet (29/ 
day). After a 2-day run-in period, pts were randomized to placebo (n=21), monotherapy 
with TLV 30mg (n=20), monotherapy with furosemide (FURO) 80mg (n=22), or both TLV 
and FURO (n=20) once daily for 7 days. Pts were on standard background therapy and 
not fluid restricted. 
Results: TLV was well tolerated. Table: Changes in body weight and urine volume on last 
study day. An increase in serum Na within the normal range was observed in TLV-treated 
pts (p<0.02 vs placebo; p<0.0f vs FURO). No changes in serum potassium, other lab 
values or BP were observed. Reductions in leg edema, dyspnea, JVP, rales and 
hepatomegaly were also noted in the TLV-traated pts versus placebo. 
Conclusions: In pts with HF and signs of volume overload, TLV monotherapy without 
concomitant loop diuretic therapy reduced body weight and lessened edema when com- 
pared to placebo, without adverse changes in serum electrolytes. These findings support 
a potential therapeutic role of inhibiting vasopressin excess in pts with HF. 
Change from baseline: Placebo TLV FURO TLV+FURO 
Body Wt (kg) +0.72±.2.42 -1.37±1.61" -0.54±1.59 -1.13+1.49" 
Urine output (ml/24hr) +423±786 +2646+1503 *+ +894±853* +2595:P2119 *+ 
* p<0.01 vs baseline 
+ p<0.001 vs FURO 
Noon 
810-5 Impact of BEST and COPERNICUS on Overall Estimates 
of Beta-Blocker Survival Benefit in Heart Failure: An 
Updated Mats-Analysis of Randomized Trials 
I~q, yid J. Bradley, Nell R. Powe, Kenneth L. Baughman, Johns Hopkins Hospital, 
Baltimore, Maryland. 
Background: Previous meta-analyses have shown a reduction in mortality among heart 
failure patients treated with beta-blockers. These meta-analyses, however, did not 
include the results of the recently published Beta-Blocker Evaluation of Survival Trial 
(BEST), a large study which did not demonstrate improved survival among heart failure 
patients treated with beta-blockers. In order to assess the impact of BEST on the overall 
estimated efficacy of beta-blockers in symptomatic heart failure, we conducted a mats- 
analysis. We also included the recently published Carvedilol Prospective Randomized 
Cumulative Survival Study (COPERNICUS) in our meta-analysis. 
Methods: Medline and the Cochrane Controlled Trials Register were searched for ran- 
domized controlled trials comparing beta-blockers versus placebo among patients with 
symptomatic left ventricular systolic dysfunction. Twenty-six randomized trials that 
enrolled 15,369 patients were identified, Trials were reviewed independently by two rat- 
ers. Abstracted data included patient exclusion criteria, patient baseline characteristics, 
trial interventions, tdal outcomes, and trial quality. 
Results: Trials were published between 1985 and 2001. Ten trials randomized patients 
to metoprolol, and 9 to carvediloL Baseline ejection fraction ranged from 16% to 34%. 
BEST recorded nearly as many deaths (860) as 24 previously published trials combined 
(1094). Using a random effects model, the pooled odds ratio of death among patients 
treated with beta-blockers versus placebo in 24 trials published before BEST and 
COPERNICUS was 0.65 (95% confidence interval (CI) 0.57 - 0.74). Pooling of mortality 
data from BEST with these previously published 24 trials increased the odds ratio of 
death from 0.65 to 0.73 (95% CI 0.66 - 0.81). tnclusion of mortality data from both BEST 
and COPERNICUS in the mats-analysis yielded an odds ratio of death of 0.71 (95% CI 
0.65 - 0.78). 
Conclusion: Although BEST was a large trial with a negative mortality endpoint, it has 
only modestly diminished the overall estimated survival benefit of beta-blockers in the 
treatment of symptomatic heart failure. 
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Spironolactone Reverses Myocyte Disarray and 
Intereetitial Fibrosis in the Cardiac Troponln T 
Transgenic Mouse Model of Hypertrophic 
Csrdiomyopathy 
Rainikant patal. Shintaro Nemoto, Gilberto DeFraitas, Tripti Halder, Silvia Lutucuta, 
Natalia Tsyboulev, Lorraine Salek, Robert Roberts, Blase Carabello, All J. Marian, Baylor 
College of Medicine, Houston, Texas. 
Hypertrophic cardiomyopathy (HCM), the most common cause of sudden cardiac death 
(SCD) in the young, is caused by mutation in sarcomeric proteins. It is characterized by 
hypertrophy, myocyte disarray, and interstitial fibrosis. We have proposed that hypertro- 
phy, disarray, and fibrosis, major predictors of SCD, are secondary to activation of 
trophic/mitotic factors and intracellular signaling kinases, and thus, are reversible. We 
performed a randomized study to determine the effects of blockade of aldosterone, a 
major mitotic and pro-fibrotic factor, on cardiac phenotypes in the cardiac troponin T- 
glutamine92 (cTnT-Q92) transgenic mice, shown to exhibit significant myocyte disarray 
and interstitial fibrosis. We randomized 26 adult cTnT-Q92 mice to treatment with 
spironolactone (50 mg/kg/d) or placebo (olive oil) for 10 weeks and included 13 non- 
transgenics (non-tg) as controls. We performed M-mode, 2D, and Doppler echocardio- 
graphy prior to and at the completion. There were no significant differences in body 
weight, heart weight, their ratio, male/female ratio, mean age, and heart rates among the 
three groups. Myocyte disarray in non-tg, placebo, and spironolactone groups were 
4.4±2.0, 22.8±9.8, 10.2±3.1% of the myocardium, respectively (p<0.001). Collagen vol- 
ume fraction were (3.4±1.9, 7.2:1:5.9, and 2.8i-0.9%, respectively p=0.001 ). Left ventricu- 
lar end diastolic diameter was smaller (4.3±0.4, 4.1_+0.3, 3.9±0.2, p=0.008) and E/A ratio 
was improved in spironolactone group. Wall thickness and fractional shortening were 
unchanged. Expression levels of activated, but not total, ERK1/2 were increased in the 
placebo and was normalized in spironolectone groups. Levels acticated p38 kinase, 
JNKs, GTP-bound and total Ras, Rac and Rho were unchanged. A duplicate study (n=8 
mice per group) connfirmed the results and showed a 50% reduction in myocyte disarray 
and fibrosis with spironolactone. Thus, myocyte disarray and interstitial fibrosis, the 
pathological hallmarks of HCM and major predictors of SCD, could be reversed with 
aldosterone antagonist, spironolactone. These results in a genetic animal model of HCM, 
beckons clinical studies in human patients with HCM. 
11:15 a.m. 
813-2 Clinical Markers for the Identification of Gene Carriers 
in Naxos Disease Families 
Nikos Protonotarios. Adalena Tsatsopoulou, Ads Anastasakis, Elias Sevdalis, Artamisia 
Theopistou, Antigone Milieu, Angelos Rigopoulos, EvangeUa Karvouni, Chdstodoulos 
Stefanadis, PavIos Toutouzas, Cardiology Dept., University of Athens, Athens, Greece, 
Yiannis Protonotarios Medical Center, Naxos, Greece. 
Background: Naxos disease is a syndrome of arrhythmogenic dght ventdcular cardiomy- 
opethy (ARVC) with autosomal recessive inheritance. The responsible pathogenic gene 
is that of plakoglobin, a constituent of the cardiac and skin cells desmosomes and adher- 
ence junctions. We genotyped patients and members of ARVC families trying to identity 
the clinical characteristics of each genctyped group (homozygous, heterozygous, nor- 
reals). 
Methods: We studied 78 individuals from 12 families (28 patients and 50 family members 
without the stereotype phenotype). Genetic screening involved DNA extraction from 
venous blood, multiplication of a 2Kb area around the PK2157de12 site of the gene 
(where the mutation appears by deletion of 2 bases) by using polymerase chain reaction 
with specifically designed pdmers. Restriction enzyme analysis, using the restriction 
endonucleaseBst01, vedfies the presence or not of the mutation. Clinical assessment 
involved clinical examination, electrocardiography and echocardiography. We performed 
sensitivity-specificity analysis in order to identity specific clinical markers for the gone 
carriers. 
Results: All 28 Naxos ARVC patients were homozygous for the PK2157de12. Among 50 
family members without the stereotype phenotype, 40 were gone carriers (hetarozygous) 
and f0 possessed normal alleles. Curly hair was present in all 28 Naxos ARVc patients, 
in 15 of the 40 gene carriers and in none of the normals (specificity 100%, sensitivity 
37,5% for the heterozygous). Palmoplantar keratoderma was only present in all homozy- 
gous (patients). T wave inversion in lead V3 was present in 20/28 patients, 1/40 het- 
erozygous and 0/10 normals (specificity 100%, sensitivity 2.5% for the tieterozygous). 
Right ventricular outflow tract (RVOT) dilatation (>31ram) was present in 15/28 patients, 
3/40 hetarozygous and 0/10 normals (specificity 100%, sensitivity 53.5% for the het- 
erozygous). 
Conclusion: All Naxos disease patients were homozygous for the plakoglobin gene muta- 
tion. Curly hair, T wave inversion and RVOT enlargement seem to be specific markers for 
identifying the gene carriers among the members of Naxos ARVC families. 
